 Jill Slansky
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Vaccines | 13 | 2021 | 137 | 2.960 |
Why?
| | Receptors, Antigen, T-Cell | 14 | 2023 | 615 | 2.730 |
Why?
| | CD8-Positive T-Lymphocytes | 18 | 2023 | 687 | 2.650 |
Why?
| | Neoplasms | 12 | 2023 | 2097 | 2.240 |
Why?
| | Antigens, Neoplasm | 12 | 2023 | 221 | 2.230 |
Why?
| | T-Lymphocytes | 13 | 2023 | 1736 | 2.100 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2023 | 111 | 1.940 |
Why?
| | Vaccines, Subunit | 4 | 2013 | 41 | 1.230 |
Why?
| | Peptides | 8 | 2023 | 848 | 1.060 |
Why?
| | T-Lymphocytes, Cytotoxic | 6 | 2022 | 154 | 0.970 |
Why?
| | Epitopes, T-Lymphocyte | 6 | 2012 | 170 | 0.970 |
Why?
| | Immunotherapy | 7 | 2021 | 474 | 0.810 |
Why?
| | Mice, Inbred BALB C | 16 | 2021 | 1143 | 0.790 |
Why?
| | Granzymes | 1 | 2022 | 40 | 0.780 |
Why?
| | Lymphocyte Activation | 11 | 2019 | 1037 | 0.750 |
Why?
| | Tumor Escape | 3 | 2019 | 35 | 0.730 |
Why?
| | Baculoviridae | 3 | 2009 | 44 | 0.690 |
Why?
| | Antigen Presentation | 6 | 2018 | 188 | 0.690 |
Why?
| | Neoplasms, Experimental | 2 | 2021 | 151 | 0.680 |
Why?
| | Immunomodulation | 1 | 2020 | 84 | 0.660 |
Why?
| | Immunogenetic Phenomena | 1 | 2019 | 6 | 0.650 |
Why?
| | Peptide Library | 4 | 2013 | 81 | 0.650 |
Why?
| | Epitopes | 2 | 2020 | 435 | 0.630 |
Why?
| | Insecta | 3 | 2009 | 64 | 0.620 |
Why?
| | Histocompatibility Antigens Class I | 6 | 2019 | 172 | 0.620 |
Why?
| | Major Histocompatibility Complex | 4 | 2008 | 217 | 0.600 |
Why?
| | Alternative Splicing | 1 | 2019 | 187 | 0.570 |
Why?
| | Animals | 43 | 2023 | 31694 | 0.570 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1141 | 0.540 |
Why?
| | H-2 Antigens | 4 | 2008 | 110 | 0.540 |
Why?
| | Mice | 30 | 2023 | 14860 | 0.520 |
Why?
| | Autoimmunity | 2 | 2020 | 813 | 0.510 |
Why?
| | Colorectal Neoplasms | 5 | 2019 | 615 | 0.510 |
Why?
| | Tumor Microenvironment | 5 | 2023 | 430 | 0.510 |
Why?
| | Neoplasm Proteins | 2 | 2018 | 384 | 0.480 |
Why?
| | Vaccines | 2 | 2010 | 375 | 0.480 |
Why?
| | Antigens | 3 | 2019 | 318 | 0.470 |
Why?
| | Up-Regulation | 3 | 2019 | 807 | 0.460 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2019 | 959 | 0.430 |
Why?
| | Colonic Neoplasms | 3 | 2012 | 215 | 0.430 |
Why?
| | B-Lymphocytes | 1 | 2017 | 766 | 0.400 |
Why?
| | Allergy and Immunology | 1 | 2013 | 51 | 0.400 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 43 | 0.400 |
Why?
| | Antigenic Variation | 1 | 2011 | 9 | 0.390 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 11 | 0.390 |
Why?
| | Breast Neoplasms | 3 | 2018 | 1862 | 0.380 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 73 | 0.370 |
Why?
| | Cell Cycle Proteins | 6 | 1997 | 551 | 0.350 |
Why?
| | Carrier Proteins | 6 | 1997 | 695 | 0.340 |
Why?
| | Histocompatibility Antigens | 2 | 2020 | 98 | 0.330 |
Why?
| | DNA-Binding Proteins | 8 | 2018 | 1314 | 0.330 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 961 | 0.330 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 382 | 0.320 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 309 | 0.310 |
Why?
| | Liver Neoplasms | 4 | 2020 | 506 | 0.310 |
Why?
| | Mice, Transgenic | 5 | 2023 | 1947 | 0.300 |
Why?
| | Tetrahydrofolate Dehydrogenase | 4 | 1997 | 14 | 0.300 |
Why?
| | Inflammation | 4 | 2020 | 2477 | 0.300 |
Why?
| | Cross Reactions | 2 | 2020 | 117 | 0.270 |
Why?
| | Vaccination | 3 | 2010 | 1204 | 0.270 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2177 | 0.270 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 157 | 0.260 |
Why?
| | Immune Tolerance | 1 | 2008 | 323 | 0.260 |
Why?
| | Disease Models, Animal | 3 | 2021 | 3531 | 0.250 |
Why?
| | Flow Cytometry | 6 | 2016 | 1083 | 0.250 |
Why?
| | Humans | 34 | 2022 | 114623 | 0.250 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2003 | 352 | 0.240 |
Why?
| | Graft Rejection | 2 | 2007 | 513 | 0.240 |
Why?
| | Cell Line, Tumor | 9 | 2021 | 2710 | 0.220 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2012 | 195 | 0.220 |
Why?
| | Models, Biological | 1 | 2010 | 1620 | 0.220 |
Why?
| | Listeria monocytogenes | 3 | 2011 | 111 | 0.220 |
Why?
| | Lymphocyte Count | 4 | 2017 | 133 | 0.210 |
Why?
| | Transcription Factors | 6 | 1997 | 1528 | 0.210 |
Why?
| | Amino Acid Substitution | 2 | 2020 | 262 | 0.200 |
Why?
| | Female | 22 | 2021 | 59466 | 0.200 |
Why?
| | Aging | 2 | 2011 | 1618 | 0.200 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1355 | 0.200 |
Why?
| | Dendritic Cells | 3 | 2014 | 435 | 0.190 |
Why?
| | Base Sequence | 7 | 2016 | 2114 | 0.190 |
Why?
| | Histocompatibility Antigen H-2D | 4 | 2022 | 21 | 0.190 |
Why?
| | Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 7 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 117 | 0.180 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 38 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2019 | 193 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 172 | 0.170 |
Why?
| | Gene Editing | 1 | 2020 | 57 | 0.170 |
Why?
| | Chemokines, CXC | 1 | 2019 | 60 | 0.170 |
Why?
| | CRISPR-Cas Systems | 1 | 2020 | 78 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.160 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2019 | 37 | 0.160 |
Why?
| | Gene Transfer Techniques | 1 | 2020 | 147 | 0.160 |
Why?
| | Nanotechnology | 1 | 2020 | 113 | 0.160 |
Why?
| | Mutation | 5 | 2020 | 3344 | 0.160 |
Why?
| | Mice, Knockout | 4 | 2021 | 2565 | 0.160 |
Why?
| | Oligopeptides | 1 | 2000 | 236 | 0.160 |
Why?
| | Interleukin-12 | 1 | 2019 | 110 | 0.160 |
Why?
| | Calcineurin | 1 | 2019 | 89 | 0.160 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 22 | 0.160 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 304 | 0.150 |
Why?
| | Genetic Therapy | 1 | 2020 | 257 | 0.150 |
Why?
| | Autoantigens | 1 | 2021 | 396 | 0.150 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 64 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.150 |
Why?
| | Promoter Regions, Genetic | 5 | 1997 | 1131 | 0.150 |
Why?
| | Cell Line | 2 | 2016 | 2635 | 0.150 |
Why?
| | Tryptophan | 1 | 2018 | 136 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 198 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2018 | 147 | 0.140 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 150 | 0.140 |
Why?
| | Immunodominant Epitopes | 2 | 2010 | 25 | 0.140 |
Why?
| | Transcriptional Activation | 2 | 2018 | 337 | 0.140 |
Why?
| | Genetic Engineering | 2 | 2009 | 80 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.140 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 58 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 439 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 139 | 0.140 |
Why?
| | Immunophenotyping | 1 | 2017 | 274 | 0.140 |
Why?
| | Ligands | 4 | 2018 | 561 | 0.130 |
Why?
| | Spodoptera | 2 | 2021 | 36 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2016 | 740 | 0.130 |
Why?
| | Mononuclear Phagocyte System | 1 | 2016 | 12 | 0.130 |
Why?
| | Emulsions | 1 | 2016 | 42 | 0.130 |
Why?
| | Papillomavirus Infections | 1 | 2019 | 261 | 0.130 |
Why?
| | Lymph Nodes | 2 | 2016 | 419 | 0.130 |
Why?
| | Gene Expression Regulation | 4 | 2022 | 2319 | 0.130 |
Why?
| | Ovarian Neoplasms | 1 | 2020 | 388 | 0.130 |
Why?
| | Lung | 3 | 2017 | 3558 | 0.130 |
Why?
| | Phagocytes | 1 | 2016 | 90 | 0.130 |
Why?
| | Cell Separation | 1 | 2016 | 291 | 0.120 |
Why?
| | Head and Neck Neoplasms | 1 | 2019 | 427 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 4 | 2007 | 383 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 590 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1993 | 270 | 0.120 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 993 | 0.120 |
Why?
| | Interferon-gamma | 5 | 2011 | 719 | 0.120 |
Why?
| | Retinoblastoma-Binding Protein 1 | 6 | 1997 | 22 | 0.120 |
Why?
| | E2F Transcription Factors | 6 | 1997 | 55 | 0.110 |
Why?
| | Prognosis | 2 | 2020 | 3328 | 0.110 |
Why?
| | Transcription Factor DP1 | 5 | 1997 | 21 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2010 | 1518 | 0.110 |
Why?
| | Colorado | 2 | 2013 | 4099 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2012 | 339 | 0.100 |
Why?
| | Molecular Sequence Data | 8 | 2006 | 2785 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 797 | 0.100 |
Why?
| | Transcription, Genetic | 3 | 1997 | 1313 | 0.100 |
Why?
| | Lymphoma, B-Cell | 1 | 2012 | 86 | 0.090 |
Why?
| | Hemangiosarcoma | 1 | 2010 | 18 | 0.090 |
Why?
| | Universities | 1 | 2013 | 339 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2019 | 4689 | 0.090 |
Why?
| | Carcinoma | 1 | 2011 | 198 | 0.090 |
Why?
| | Research | 1 | 2013 | 394 | 0.080 |
Why?
| | Down-Regulation | 1 | 2011 | 594 | 0.080 |
Why?
| | Genes, MHC Class I | 1 | 2009 | 32 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 281 | 0.080 |
Why?
| | Cross-Priming | 1 | 2008 | 18 | 0.080 |
Why?
| | E2F1 Transcription Factor | 4 | 1997 | 57 | 0.070 |
Why?
| | CD11c Antigen | 1 | 2008 | 38 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2009 | 206 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 698 | 0.070 |
Why?
| | Protein Conformation | 2 | 2003 | 805 | 0.070 |
Why?
| | Biomarkers | 1 | 2017 | 3408 | 0.070 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 342 | 0.070 |
Why?
| | RNA, Messenger | 2 | 1994 | 2552 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6344 | 0.070 |
Why?
| | Male | 8 | 2020 | 55554 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2006 | 57 | 0.070 |
Why?
| | Melanoma, Experimental | 1 | 2006 | 89 | 0.060 |
Why?
| | Drug Design | 1 | 2006 | 148 | 0.060 |
Why?
| | DNA Primers | 1 | 2006 | 510 | 0.060 |
Why?
| | Amino Acid Sequence | 5 | 2018 | 1982 | 0.060 |
Why?
| | S Phase | 2 | 1996 | 69 | 0.060 |
Why?
| | G1 Phase | 2 | 1996 | 68 | 0.060 |
Why?
| | Antigens, Surface | 2 | 2001 | 146 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2011 | 3881 | 0.060 |
Why?
| | Clone Cells | 2 | 2003 | 247 | 0.060 |
Why?
| | Middle Aged | 3 | 2020 | 26719 | 0.060 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2003 | 26 | 0.060 |
Why?
| | 3T3 Cells | 4 | 2003 | 140 | 0.050 |
Why?
| | Genes, erbB-2 | 1 | 2003 | 26 | 0.050 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 64 | 0.050 |
Why?
| | Aged | 2 | 2017 | 19061 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 57 | 0.050 |
Why?
| | Molecular Conformation | 1 | 2022 | 135 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2003 | 413 | 0.050 |
Why?
| | Transglutaminases | 1 | 2022 | 142 | 0.050 |
Why?
| | Sf9 Cells | 1 | 2021 | 9 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2001 | 53 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 62 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2001 | 142 | 0.050 |
Why?
| | Alanine | 1 | 2000 | 104 | 0.040 |
Why?
| | Surface Plasmon Resonance | 1 | 2000 | 81 | 0.040 |
Why?
| | Mice, SCID | 1 | 2021 | 314 | 0.040 |
Why?
| | Dogs | 2 | 2012 | 334 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1230 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 555 | 0.040 |
Why?
| | Cyclophosphamide | 2 | 2011 | 217 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2006 | 756 | 0.040 |
Why?
| | Models, Molecular | 1 | 2003 | 1369 | 0.040 |
Why?
| | Paraparesis, Tropical Spastic | 1 | 1998 | 1 | 0.040 |
Why?
| | Gene Products, tax | 1 | 1998 | 9 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 299 | 0.040 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 1998 | 12 | 0.040 |
Why?
| | Kynurenine | 1 | 2018 | 81 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 3 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 296 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1121 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 630 | 0.040 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 98 | 0.040 |
Why?
| | Antigens, Viral | 1 | 1998 | 176 | 0.040 |
Why?
| | Antigens, CD | 2 | 2014 | 442 | 0.030 |
Why?
| | HLA Antigens | 1 | 2018 | 224 | 0.030 |
Why?
| | High-Throughput Screening Assays | 1 | 2018 | 123 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1644 | 0.030 |
Why?
| | Folic Acid Antagonists | 1 | 1996 | 8 | 0.030 |
Why?
| | Sp1 Transcription Factor | 1 | 1996 | 23 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1996 | 84 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 520 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 931 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1996 | 81 | 0.030 |
Why?
| | Gene Amplification | 1 | 1996 | 95 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 299 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 22 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 910 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 11 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 26 | 0.030 |
Why?
| | DNA | 3 | 1997 | 1352 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 51 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 35 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 57 | 0.030 |
Why?
| | DNA Replication | 1 | 1996 | 202 | 0.030 |
Why?
| | Cell Division | 2 | 1993 | 758 | 0.030 |
Why?
| | Cell Cycle | 2 | 1994 | 542 | 0.030 |
Why?
| | Imidazoles | 1 | 2014 | 208 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2796 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 1993 | 42 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 1996 | 284 | 0.030 |
Why?
| | Serum Response Factor | 1 | 1993 | 29 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1879 | 0.030 |
Why?
| | Cloning, Molecular | 3 | 2001 | 522 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2380 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 430 | 0.020 |
Why?
| | Proteomics | 1 | 2018 | 836 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4411 | 0.020 |
Why?
| | Cytokines | 1 | 2019 | 1840 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 2011 | 79 | 0.020 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2011 | 68 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 76 | 0.020 |
Why?
| | Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2010 | 11 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 385 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 385 | 0.020 |
Why?
| | Doxorubicin | 1 | 2012 | 285 | 0.020 |
Why?
| | ras Proteins | 1 | 2010 | 138 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1226 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 1993 | 591 | 0.020 |
Why?
| | Protein Binding | 2 | 2006 | 1889 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1211 | 0.020 |
Why?
| | DNA, Complementary | 2 | 2001 | 256 | 0.020 |
Why?
| | Vaccines, Attenuated | 1 | 2007 | 112 | 0.020 |
Why?
| | Binding Sites | 3 | 1997 | 1168 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2003 | 665 | 0.020 |
Why?
| | Injections, Intradermal | 1 | 2006 | 12 | 0.020 |
Why?
| | Enterotoxins | 1 | 2006 | 88 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 228 | 0.020 |
Why?
| | Hepatitis | 1 | 2006 | 45 | 0.020 |
Why?
| | Adult | 2 | 2017 | 30528 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2006 | 431 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2007 | 380 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 43 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2003 | 43 | 0.010 |
Why?
| | Vaccines, DNA | 1 | 2003 | 29 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2003 | 60 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 133 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 140 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2003 | 198 | 0.010 |
Why?
| | Drug Synergism | 1 | 2003 | 316 | 0.010 |
Why?
| | Adoptive Transfer | 1 | 2003 | 195 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2003 | 396 | 0.010 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2001 | 14 | 0.010 |
Why?
| | CD28 Antigens | 1 | 2001 | 47 | 0.010 |
Why?
| | Gene Library | 1 | 2001 | 114 | 0.010 |
Why?
| | Dimerization | 1 | 2001 | 176 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 353 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2001 | 171 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2001 | 289 | 0.010 |
Why?
| | Image Cytometry | 1 | 1998 | 5 | 0.010 |
Why?
| | HTLV-I Infections | 1 | 1998 | 21 | 0.010 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 1998 | 23 | 0.010 |
Why?
| | HLA-A2 Antigen | 1 | 1998 | 36 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 616 | 0.010 |
Why?
| | Immunity, Active | 1 | 1998 | 9 | 0.010 |
Why?
| | E2F5 Transcription Factor | 1 | 1997 | 1 | 0.010 |
Why?
| | E2F4 Transcription Factor | 1 | 1997 | 6 | 0.010 |
Why?
| | Immunologic Memory | 1 | 1998 | 313 | 0.010 |
Why?
| | HeLa Cells | 1 | 1997 | 562 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 908 | 0.010 |
Why?
| | Rats | 1 | 2003 | 4958 | 0.010 |
Why?
| | Models, Genetic | 1 | 1997 | 562 | 0.010 |
Why?
| | Genes | 1 | 1994 | 223 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 1994 | 487 | 0.010 |
Why?
| | Molecular Weight | 1 | 1992 | 331 | 0.010 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1992 | 345 | 0.010 |
Why?
| | Transfection | 1 | 1992 | 866 | 0.010 |
Why?
|
|
Slansky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|